Ascendis Pharma Expands TransCon™ PTH Phase 2 PaTH Forward Clinical Trial to Expedite Enrollment of Subjects Previously Treated with NATPARA® in the United States

    NEXT STORY
    CorMedix Inc. Reports Third Quarter 2019 Financial Results and Provides Business Update
    PREV STORY
    Global Endoscope Market is Set to Reach USD 32.8 billion by 2024, Observing a CAGR of 7.5% during 2019–2024: VynZ Research
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Aquinox Pharmaceuticals Announces First Quarter 2017 Financial Results

    VANCOUVER, British Columbia, May 09, 2017 (GLOBE NEWSWIRE) -- Aquinox Pharmaceuticals, Inc. (“Aquinox”) (NASDAQ:AQXP), ...

    author_avatar
    NASDAQ Market News

    Biocartis Group NV: Biocartis kondigt CE-IVD markering van zijn Idylla(TM) MSI Test aan

    author_avatar
    NASDAQ Market News

    Recro Pharma Receives Complete Response Letter from the FDA

    Company to Host Conference Call Today at 8:00 AM ETMALVERN, Penn., May 24, 2018 ...

    author_avatar
    NASDAQ Market News